Polymyositis and rhabdomyolysis caused by hepatocellular carcinoma - Case report and literature review

Dávid Bárdos, Maria Judit Molnár, Ibolyka Dudás, Sebestyén Tuza, Attila Szijártó, Oskár Hahn

ABSTRACT

Introduction: Rhabdomyolysis is a syndrome characterized by a rapid necrosis of muscle fibers and the release of muscle-derived metabolic products into the circulatory system. A rare cause of rhabdomyolysis is paraneoplastic polymyositis.

Case presentation: A 67-year-old man was diagnosed with paraneoplastic polymyositis and rhabdomyolysis caused by hepatocellular carcinoma (HCC). Intravenous steroid was used as a symptomatic therapy for rhabdomyolysis, and the tumour was removed by left hemihepatectomy to treat the underlying cause. After muscle strength gradually improved, steroid therapy was discontinued. The patient was reoperated multiple times due to bleeding and bile leakage. Following the operations, his overall state and muscle strength further improved. Despite that, the patient’s condition worsened again, and eventually, he died of candida albicans pneumonia and sepsis.

Discussion: HCC is an extremely rare cause of paraneoplastic polymyositis and rhabdomyolysis. Treatment is challenging, as none of the few available case reports record long term survival and less than half of the reports record muscle strength improvement. In our case, the patient was treated with systemic steroid therapy and resection of the tumour. The patient’s muscle strength temporarily improved, but subsequently, the patient died.

Conclusion: Our case confirms the importance of a definitive treatment of HCC, as we achieved a significant improvement in muscle strength by removing the tumour. On the other hand, our paper highlights the dangers of double-sided steroid therapy, which, combined with the essential, effective treatment of rhabdomyolysis, may have contributed to the development of postoperative complications and candida sepsis leading to death.

1. Introduction

Rhabdomyolysis is a syndrome characterized by the rapid necrosis of muscle fibers and the release of muscle-derived metabolic products into the circulatory system. The classic triad of symptoms is muscle weakness, muscle pain and tea-brown urine. The gold standard examination is serum creatinine kinase (CK) test, which shows at least 5-fold, but usually more than 10-fold elevation from the normal value [1,2]. A common, dangerous consequence of rhabdomyolysis is renal failure caused by metabolic products accumulating in the bloodstream. Rhabdomyolysis can be caused by trauma, heavy physical exertion, drugs, inherited neuromuscular diseases, or other systemic causes [3]. Systemic causes include paraneoplastic polymyositis as well. According to a review, the most common causes of paraneoplastic polymyositis are lung cancer and non-Hodgkin lymphoma [4]. However, another study found lung, ovary, breast, colorectal and nasopharyngeal tumours the most likely to develop paraneoplastic polymyositis and dermatomyositis [5]. In this paper, we present a rare case of rhabdomyolysis developed due to paraneoplastic polymyositis caused by hepatocellular carcinoma.

There are only seven documented cases of paraneoplastic polymyositis associated with hepatocellular carcinoma in the international literature, out of which only four cases resulted in rhabdomyolysis.

In the first case of the rhabdomyolysis group, polymyositis was treated with intravenous steroid therapy and hemodialysis due to the...
acute renal failure. The patient’s renal function improved, but his muscle strength did not. Prior to his planned chemotherapy treatment, the patient died of tumour rupture [6]. In another case, the patient’s muscle symptoms regressed after steroid therapy and liver resection, but the patient died of pulmonary embolism shortly after the surgery [7]. In a third case, a patient with Hepatitis B-induced cirrhosis was treated for liver failure when first liver cancer, and then rhabdomyolysis was detected. He received fluid therapy to prevent kidney failure and was not treated with steroids. The patient died of liver failure on day 30 of admission [8]. In a fourth case, a hepatitis B positive cirrhotic patient with bilobary located irresectable tumour was diagnosed with rhabdomyolysis [9].

In three other cases, rhabdomyolysis was not diagnosed in addition to HCC-induced paraneoplastic polymyositis. In one case, the patient was treated with steroids, and the patient refused TACE treatment for his irresectable tumour. His muscle strength did not improve, and he died of liver failure within two months [10]. In another case, the patient was treated with steroids and metotrexate and died within 3 months [11]. Finally, a further case described HCC-induced polymyositis in which the patient’s symptoms and elevated CK improved after liver resection without pharmacotherapy [12].

Five out of the seven patients were male, the patients’ age varied between 37 and 72 years. All but one of the patients were first examined for musculoskeletal symptoms, and one for cirrhosis. Among the patients, tumour-free liver parenchyma abnormalities were found in two cases, both patients had hepatitis B virus-positive (HBV +) cirrhosis. Liver parenchyma was not described in the other cases. Rhabdomyolysis caused kidney failure in only one case, which improved after successful treatment. Serum creatinine kinase levels were elevated in all available cases at the time of diagnosis and were decreased in all reported cases, mostly to normal level. In six of the seven cases, polymyositis was treated with steroids, supplemented in one case with metotrexate and in one case with nonsteroidal anti-inflammatory drugs. Surgery was performed in two cases, TACE treatment was applied in two other cases, and the tumour was not treated in the remaining cases. Muscle strength improved in three cases, in one case in the rhabdomyolysis group (the patient who was treated with surgery) and in two patients in the group without rhabdomyolysis.

The findings of the case reports are summarized in Table 1. HCC-related polymyositis was described in 5 additional cases in which polymyositis was considered to be a drug side effect [13–17].

### 2. Presentation of the case

This case is presented in line with the SCARE 2020 criteria [18]. A 67-year-old caucasian man was referred by his family physician to our surgery department with progressive fatigue, muscle weakness, and a weight loss of 11 kg that had started six weeks before. Earlier, he had had no symptoms and his muscle strength had been normal. Within six weeks, he developed swallowing difficulties and severe, predominantly proximal muscle weakness in all four limbs. He was unable to stand up and walk without assistance.

He had a history of hypertension, diabetes mellitus type 2, central retinal vein occlusion, vitrectomy due to vitreous hemorrhage, and open repair of scrotal hernia.

Laboratory test confirmed extremely high CK values (CK 15,409 IU/

### Table 1

HCC-induced polymyositis and rhabdomyolysis – literature review.

| Author        | Kim [6] | Kishore [7] | Gidangaya [9] | Thanaprom [11] | Tekaya [10] | Iba-Ba [11] | Hasegawa [12] |
|---------------|---------|-------------|---------------|----------------|-------------|-------------|---------------|
| **Age**       | 55      | 50          | 73            | 56             | 72          | 37          | 70            |
| **Sex**       | man     | woman       | woman         | man            | man         | man         | man           |
| **Muscle symptoms** | progressive proximal muscle weakness of the lower limbs | proximally more severe progressing symmetrical quadriaparesis and neck weakness | lower extremity weakness | proximally 4 limb weakness | proximally more severe 4 limb weakness | proximally limbmuscles and neck muscles | proximal weakness of the lower limbs |
| **Kidney function** | oliguria, acute renal failure solved by hemodialysis | normal | normal | not mentioned | not mentioned | normal | normal |
| **First symptoms** | weakness | weakness for 6 weeks | cirrhosis | weakness and fever | weakness | arthromyalgia | weakness for 1 year |
| **Tumour-free liver parenchyma** | normal | normal | HBV + cirrhosis | HBV + cirrhosis | normal | normal | normal |
| **Initial CK** | 40,000 | 1972 | 3554 | 17963 | 1710 | ~1500 | 1443 |
| **Rhabdomyolysis** | yes | yes | yes | yes | no | no | no |
| **Polymyositis therapy** | 1 mg/kg methylprednisolone for 5 weeks | 1 mg/kg methylprednisolone for 5 weeks | supportive to prevent renal failure | 1 mg/kg prednisolone | corticosteroid and non-steroid | bolus 750 mg/d for 3 days then 50 m/week methylpredrate, 50 mg corticosteroid | none |
| **Tumour therapy** | chemotherapy planned but patient died | left hepatolobectomy | none | TACE | TACE planned but patient denied | TACE planned but patient refused | best supportive care |
| **Renal function after treatment** | improved | normal | normal | normal | not mentioned | not mentioned | not mentioned |
| **Muscle weakness after treatment** | no significant improvement | significant improvement | not mentioned | persisted | persisted | improved | improved |
| **Post-treatment CK** | unknown | died in tumour rupture | normal | 185 | normal | normal | normal |
| **Follow-up** | died in tumour embolism | died in pulmonary embolism | died in hepatic pneumonia | died in hepatic failure | died in hepatic failure | died in hepatic failure | died in hepatic failure |
| **Survival from the onset of symptoms** | about 60 days | about 6.5 mo | 1 mo | 6.5 mo | 5 mo | not mentioned | alive after 16 mo |
| **Survival from the diagnosis** | 54 days | about 4 mo | 1 mo | 5 mo | 2 mo | 3 mo | alive after 1 mo |
Renal function was normal (creatinine 46 μM/L, GFR [glomerular filtration rate] > 90 mL/min/1.73 m²). He had no history of trauma, heavy physical exertion, or drug/toxic abuse. The patient had not received any new medication in the period leading up to the examination. Immunological studies had ruled out autoimmune origin, as anti-DNA (anti-Deoxyribonucleic Acid), antinuclear antibody, antiposomal ANCA (Anti-Neutrophil Cytoplasmic Antibody), ANCA Myeloperoxidase EIA/CIA, proteinase 3-ANCA at EIA/CIA, anti- Jo, ANTI Mi, SSA and SSB (Sjogren Syndrome A and B), CCP (cyclic citrullinated peptide) tests were negative.

Further investigations were performed due to a suspicion of paraneoplastic syndrome. Abdominal ultrasonography found an 8 × 7 cm foreign tissue in the liver, the AFP was increased. Aspiration cytology confirmed HCC. Abdominal CT scan confirmed a 10 cm solitary mass in the liver, mainly located in segment 4 invading a smaller part of segment 2 and distracting the middle and left hepatic vein with the typical radiographic features of HCC: early arterial contrast enhancement and washout on portal venous phase with a hypodens nonenhancing necrotic central scar. No sign of metastasis was seen neither in the hilar lymph nodes, nor far away, and no other abnormality was visible on CT scan (Fig. 1). Core biopsy confirmed well-differentiated HCC. Examination of hepatitis A, B, C and E ended with a negative result. No abnormality was found on the chest X-ray.

Muscle biopsy taken from the quadriceps diagnosed inflammatory necrotizing myopathy with diffuse atrophic fibers, a great proportion of necrotic fibers and mononuclear infiltration with variable intensity in multiple locations. Immunohistochemical staining showed CD4, CD8 cells and CD68 positive fibers confirming inflammatory activity. On the surface of muscle fibers, increased MHC-1 expression was visible. Typical skin lesions and histologic changes referring to dermatomyositis were absent (Fig. 2).

Based on the findings above, we diagnosed HCC-induced paraneoplastic polymyositis and consequent rhabdomyolysis in the background of the patient’s symptoms.

To control progressive muscle weakness, we considered liver resection as the first and most important step to treat HCC. Chemotherapy and transarterial chemoembolization are non-curative techniques and, according to previous case reports, we believed they would not solve the paraneoplastic symptoms. Tumour size was too large for radiofrequency ablation (RFA). Thus, we decided to surgically remove the tumour as the first and most important step to treat paraneoplastic inflammatory myopathy and HCC. Based on imaging studies, the tumour appeared removable by left hepatolobectomy. Therefore, with the patient’s informed consent, despite of the increased risk due to his poor overall condition, surgery was planned. Preoperatively, we supplemented nutrition with a high protein oral and parenteral formula (Protifar and Kabiven). We also administered steroid therapy (methylprednisolone 125 mg iv.) 4 days before surgery.

Subsequently, open left hepatolobectomy was performed by a hepatic surgery expert in the hepatopancreato-surgical department of the surgery department of our university hospital.

Pathological examination confirmed necrotizing Grade 3 pT2 hepatocellular carcinoma with vascular invasion. The lesion reached the resection margin in the line of the vena cava (vascular R1). Tumour-free liver tissue showed typical features of portal inflammation and fibrosis.

After surgery, the patient was admitted to the intensive care unit as planned. On the fourth postoperative day, the sedation, mechanical ventilation, and circulatory support could be discontinued.

On postoperative day 2, steroid therapy was reduced to 80 mg/day methylprednisolone, and the dose was gradually reduced and eventually abandoned after five weeks. With intensive physiotherapy, bed biking and mobilization, the patient’s muscle strength gradually improved in all four limbs and the trunk. The patient was able to stand up and walk with assistance six weeks after surgery. Following the introduction of steroid therapy and surgery, serum CK levels decreased abruptly (CK 3339 IU/L on postoperative day 1) and then gradually decreased to normal range (CK 95 IU/L) over a six-week period and remained in the normal range.

On postoperative day 9, bleeding was observed through the abdominal drain, which urged an acute reoperation. During the surgery, we found that the bleeding of the resection surface of the liver had been caused by the mechanical friction of the drain. The operation was performed by an expert hepatic surgeon. Following reoperation, intensive therapeutic care was continued. After reoperation, the patient got pneumonia and sepsis, which improved after the administration of targeted antibiotic treatment. The patient’s overall condition gradually improved.

Through his remaining fistula opening at the site of his drain, we repeatedly experienced minor bleeding that did not cause circulatory fluctuations. We reoperated the patient again. During the second reoperation, hematoma evacuation and bleeding control was performed. The hematoma recurred once again and was treated with percutaneous drainage. Subsequently, bile leakage and intraabdominal fluid collection was found and the patient was reoperated again. The remaining stump of the left bile duct was necrotic and leaking, hence left hepatic duct suture and bile drainage was performed with the insertion of an open biliary T-tube (Kehr’s tube). All reoperations were performed by an expert hepatic surgeon. After a temporary improvement, his condition gradually deteriorated, and he developed sepsis again.

No complication was observed on the abdominal CT scan. On the chest CT-scan, bilateral pneumonia was seen. Tracheal aspiration culture was positive for Candida albicans, which is known to be an opportunistic pathogen. When the patient was conscious, he could squeeze his hand tightly and elevate his lower limbs when prompted.

With an increasing need for circulatory support, the patient died in sepsis and multorgan failure on the 81st postoperative day. The autopsy and post-mortem lung tissue samples confirmed bilateral candida pneumonia and candida sepsis as the cause of death, there was no abnormality in the abdomen (Fig. 3).

3. Discussion

In this paper, we described a rare case of polymyositis and
rhabdomyolysis associated with hepatocellular carcinoma. The patient was treated with corticosteroids, supplementary nutrition, and the tumour was resected. After the resection of the tumour, the clinical signs and laboratory parameters of the polymyositis regressed and the patient’s muscle strength gradually improved. The corticosteroid therapy was relatively quickly discontinued. The patient underwent multiple reoperations to control bleeding and bile leakage. Despite of an initial improvement, the patient developed candida pneumonia and candida sepsis and eventually died.

Paraneoplastic polymyositis and rhabdomyolysis are extremely rare complications of HCC. There are only seven reports of HCC-induced polymyositis in the literature [6–12], with only four cases when polymyositis was associated with rhabdomyolysis [6–9]. In six cases, polymyositis was treated with steroid therapy, in one case steroid and methotrexate were used [11], and in one case only intravenous fluid therapy was applied to prevent renal failure [8]. Elimination of the underlying cause, i.e. surgery, was performed in two cases [7,12], no surgery was performed in the other cases due to the irresectability of the tumour or the poor general condition of the patient. The muscle strength of both two operated patients improved. In contrast, among the patients who did not undergo surgery, muscle strength improved in only half of the cases, and there was no improvement in the other half. No long-term survival was reported, the longest documented survival was 6.5 months from the onset of symptoms and 5 months from diagnosis [9]. Causes of death included liver failure in two cases [8,10], tumour rupture [6], pneumonia [9], and pulmonary embolism in one case [7], respectively. Cause of death was not documented in the remaining cases.

Based on the previously documented cases and our own experience, HCC-induced polymyositis and rhabdomyolysis is a difficult-to-treat disease with poor prognosis. Therapy should cover the paraneoplastic immunologic process of rhabdomyolysis, renal failure (if presented), and the cause of the disease, HCC at the same time. This puts clinicians in a difficult position, as poor general condition and steroid therapy increases the risk of postoperative complications after liver resection. However, treatment effectiveness of less invasive ablation or embolization is questionable.

4. Conclusion

Our observation underlines the importance of a definitive surgical therapy of HCC, since we achieved a significant improvement in muscle strength by removing the tumour. On the other hand, our paper highlights the dangers of double-sided steroid therapy, which, in addition to the essential, effective treatment of rhabdomyolysis, may have contributed to the development of postoperative complications and candida sepsis leading to death.
Provenance and peer review

Not commissioned, externally peer reviewed.

Sources of funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

The institutional review board approved the article.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

Dr. Dávid Bárdos – data collection, writing the paper, assisting at surgeries

Prof. Dr. Mária Judit Molnár – study concept and design, interpreting muscle biopsy, treating rhabdomyolysis

Dr. Ibolyka Dudás – data collection, interpreting radiological findings

Dr. Sebestyén Tuza – data collection, interpreting pathological findings

Prof. Dr. Attila Szijártó – data interpretation, reoperations

Dr. Oszkár Hahn – study concept and design, data interpretation, hepatic resection, reoperations.

Trial registry number

N/a.

Guarantor

Dr. Dávid Bárdos.

Dr. Oszkár Hahn.

Declaration of competing interest

None.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.amsu.2021.102269.

References

[1] P.A. Torres, et al., Rhabdomyolysis: pathogenesis, diagnosis, and treatment, Ochsner J. 15 (1) (2015) 58–69.

[2] G. Cervellin, I. Comelli, G. Lippi, Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features, Clin. Chem. Lab. Med. 48 (6) (2010) 749–756.

[3] J.M. Sauzet, G. Marinides, G.K. Wang, Rhabdomyolysis, Am. Fam. Phys.ician 65 (5) (2002) 907–912.

[4] R. Buchbinder, C.L. Hill, Malignancy in patients with inflammatory myopathy, Curr. Rheumatol. Rep. 4 (5) (2002) 415–426.

[5] J.K. Qiang, et al., Risk of malignancy in dermatomyositis and polymyositis, J. Cutan. Med. Surg. 21 (2) (2017) 131–136.

[6] M.J. Kim, et al., Hepatocellular carcinoma, polymyositis, rhabdomyolysis, and acute renal failure, J. Kor. Med. Sci. 19 (6) (2004) 891–894.

[7] B. Kishore, V. Thurlow, B. Kenzel, Hypokalaemic rhabdomyolysis, Ann. Clin. Biochem. 44 (Pt 3) (2007) 308–311.

[8] S. Gidaagaya, et al., Acute rhabdomyolysis and chylous ascites in a patient with cirrhosis and malignant hepatic tumor, J. Formos. Med. Assoc. 113 (2) (2014) 137–138.

[9] K. Thanapirom, S. Aniwon, S. Treenprasertsuk, Polymyositis associated with hepatitis B virus cirrhosis and advanced hepatocellular carcinoma, ACG Case Rep J 1 (3) (2014) 167–169.

[10] R. Tekaya, et al., Hepatocellular carcinoma with polymyositis as an initial symptom: a case report, Acta Clin. Belg. 66 (6) (2011) 53–54.

[11] J. Iba-Ba, et al., [Polymyositis and hepatocarcinoma: a case report from Gabon], Med. Trop. 69 (6) (2009) 548.

[12] K. Haegawa, et al., Polymyositis as a paraneoplastic manifestation of hepatocellular carcinoma, Hepato-Gastroenterology 47 (35) (2000) 1425–1427.

[13] C. Dopazo, et al., Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in a liver transplant patient, Transplant. Proc. 41 (3) (2009) 1021–1024.

[14] A.G. dos Santos, et al., Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-alpha in liver-transplanted patients: a case report and literature review, Transplant. Proc. 46 (6) (2014) 1887–1888.

[15] K. Matake, et al., Rhabdomyolysis developing after transcatheter arterial chemoembolization for hepatocellular carcinoma, Cardiovasc. Intervent. Radiol. 32 (6) (2009) 1284–1287.

[16] K. Tsuji, et al., A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma, Clin J Gastroenterol 6 (3) (2013) 255–257.

[17] Alcazar Diaz, E. Mdm, Cervilla Saez de Tejada, E. Ruiz Escolano, Rhabdomyolysis in a patient under treatment with sorafenib, Rev. Esp. Enferm. Dig. 112 (3) (2020) 243–244.

[18] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, SCARE Group, The SCARE 2020 guideline: updating consensus surgical CaseReport (SCARE) guidelines, Int. J. Surg. 84 (2020 Dec) 226–230.